Not Signed In - Rigel's Janus Kinase 3 (JAK3) Inhibitors Show Benefit In Organ Transplant Model And Potential Use In Immunosuppression
Thu, 20 Jul 2006 06:00 AM EST
... RigelPharmaceuticals, Inc. (Nasdaq: RIGL) announced today that it will presentdata from preclinical studies of multiple potent and selective inhibitorsof Janus Kinase 3 (JAK3) at the 2006 World Transplant Congress taking placeJuly 22- 27th at the Hynes Convention Center in Boston, Massachusetts. [click link for full article] ...
Related Topics
- Organ Donation
- Organ Transplantation
- Organ Transplant
- Disease models
- Biopsychosocial model
- Transplantation
- Cornea & Corneal Disease
- Organ Donation And Transplantation
- Ovarian Low Malignant Potential Tumor
- Ovarian Low Malignant Potential Tumors
- Bone Marrow
- Levocarnitine Oral
- MAO Inhibitors
- COX-2 Inhibitors
- ACE Inhibitors
- Creatine
- Proton-pump Inhibitors
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Laparoscopic Organ Examination
- Biomedical model
email this page
print this page
bookmark this page
feedback on this page
